Glenmark wilts on US Finacea ruling
This article was originally published in Scrip
Executive Summary
Shares of Glenmark Pharmaceuticals weakened on Indian bourses following news that a US court had upheld a patent covering the skin treatment Finacea Gel (azelaic acid) and ruled that the firm had infringed on claims therein.